Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Hematology/Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin. 2018; 68: 394-424
- A population-based comparative effectiveness study of radiation therapy techniques in stage III non-small cell lung cancer.Int J Radiat Oncol Biol Phys. 2014; 88: 872-874
- Influence of conformal radiotherapy technique on survial after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.Cancer. 2014; 120: 2360-2368
- Association between intensity modulated radiation therapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.Lung Cancer. 2017; 108: 222-227
- 73.6Gy and beyond: hyperfrationated, accelerated radiotherapy for non-small-cell lung cancer.J Clin Oncol. 2001; 19: 705-711
- Localized non-small cell lung cancer: adjuvant radiotherapy in the era of effective systemic therapy.Clin Cancer Res. 2005; 11: 5004s-5010s
- Elective nodal failures are uncommon in medically inoperable patients with Stage I non-small-cell lung carcinoma treated with limited radiotherapy fields.Int J Radiat Oncol Biol Phys. 2003; 56: 342-347
- High-dose radiation improved local tumor control and overall survival in patients with inoperable/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study.Int J Radiat Oncol Biol Phys. 2005; 63: 324-333
- The role of stereotactic body radiotherapy in the management of non-small cell lung cancer: an emerging standard for the medically inoperable patient?.Curr Oncol Rep. 2010; 12: 235-241
- Stereotactic body radiotherapy for early stage lung cancer-historical developments and future strategies.Chin Clin Oncol. 2017; 6: S20
- Stereotactic body radiotherapy (SBRT) for Stage I lung cancer.Jpn J Clin Oncol. 2018; 48: 405-409
- American College of Surgeons Oncology Group Z4099/Radiation Therapy Oncology Group 1021: a randomized study of sublobar resection compared with stereotactic body radiotherapy for high-risk stage I non-small cell lung cancer.J Thorac Cardiovasc Surg. 2012; 144: S35-S38
- Trial of Either Surgery or Stereotactic Radiotherapy for Early Stage (IA) Lung Cancer (ROSEL).(Available at:) (Accessed June 20, 2018)
- Randomized Study to Compare CyperKnife to Surgical Resection in Stage I Non–Small Cell Lung Cancer (STARS).(Available at:) (Accessed June 20, 2018)
- Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.Lancet Oncol. 2015; 16: 630-637
- Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer (STABLE-MATES).(Available at:) (Accessed June 20, 2018)
Veteran Affairs Lung Cancer or Stereotactic Radiotherapy (VALOR). Available at: https://clinicaltrials.gov/ct2/show/NCT02984761. Accessed June 5, 2018.
- Radical Resection vs. Ablative Stereotactic Radiotherapy in Patients with Operable Stage I NSCLC (POSTILV).(Available at:) (Accessed June 20, 2018)
- A Study to Determine the Feasibility and Acceptability of Conducting a Phase III Randomised Controlled Trial Comparing Stereotactic Ablative Radiotherapy with Surgery in paTients with Peripheral Stage I Non-Small Cell Lung Cancer cOnsidered Higher Risk of Complications from Surgical Resection (SABRTOOTHv1).(Available at:) (Accessed July 31, 2019)
- Bayesian adaptive randomization trial of passive scattering proton therapy and intensity-modulated photon radiotherapy for locally advanced non-small-cell lung cancer.J Clin Oncol. 2018; 36: 1813-1822
- Consensus guidelines for implementing pencil-beam scanning proton therapy for thoracic malignancies on behalf of the PTCOG Thoracic and Lymphoma Subcommittee.Int J Radiat Oncol Biol Phys. 2017; 99: 41-50
- Phase 2 study of stereotactic body radiation therapy and stereotactic body proton therapy for high-risk, medically inoperable, early-stage non-small cell lung cancer.Int J Radiat Oncol Biol Phys. 2018; 101: 558-563
- Stereotactic body radiation therapy for operable early-stage lung cancer: findings from the NRG oncology RTOG 0618 trial.JAMA Oncol. 2018; 4: 1263-1266
- Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung Cancer: NRG Oncology/RTOG 0813 trial.J Clin Oncol. 2019; 37: 1316-1325
- Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors.Lung Cancer. 2015; 89: 50-56
- Outcomes of hypofractionated high-dose radiotherapy in poor-risk patients with “ultracentral” non-small cell lung cancer.J Thorac Oncol. 2016; 11: 1081-1089
- P2.05-056 safety of stereotactic body radiotherapy for central, ultracentral, and paramediastinal lung tumors.J Thorac Oncol. 2017; 12: S1066
- Ultracentral tumors treated with stereotactic body radiotherapy: Singleinstitution experience.Clin Lung Cancer. 2018; 19: e803-e810
- The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors.Radiother Oncol. 2018; 129: 277-283
- Tumor control and toxicity after SBRT for ultracentral, central, and paramediastinal lung tumors.Pract Radiat Oncol. 2019; 9: e196-e202
- Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.J Clin Oncol. 2010; 28: 2181-2190
- Definitive and adjuvant radiotherapy in locally advanced non-small-cell lung cancer: american society of clinical oncology clinical practice guideline endorsement of the american society for radiation oncology evidence-based clinical practice guideline.J Clin Oncol. 2015; 33: 2100-2105
- Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial.J Natl Cancer Inst. 1996; 88: 1210-1215
- Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.J Natl Cancer Inst. 2011; 103: 1452-1460
- Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: cancer and Leukemia Group B.J Clin Oncol. 2007; 25: 1698-1704
- Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.J Clin Oncol. 2008; 26: 2450-2456
- Multinational randomized phase III trial with or without consolidation chemotherapy using docetaxel and cisplatin after concurrent chemoradiation in inoperable stage III non-small-cell lung cancer: KCSG-LU05-04.J Clin Oncol. 2015; 33: 2660-2666
- Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.Lancet Oncol. 2015; 16: 187-199
- PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer.J Clin Oncol. 2016; 34: 953-962
- Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.N Engl J Med. 2018; 379: 2342-2350
- Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol.J Clin Oncol. 2005; 23: 5883-5891
- Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.J Thorac Oncol. 2011; 6: 1474-1480
- A randomized study of involved-field irradiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer.Am J Clin Oncol. 2007; 30: 239-244
- Heart dose is an independent dosimetric predictor of overall survival in locally advanced non-small cell lung cancer.J Thorac Oncol. 2017; 12: 293-301
- Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial.J Clin Oncol. 2017; 35: 56-62
- Residual setup errors towards the heart after image guidance linked with poorer survival in lung cancer patients: do we need stricter IGRT protocols?.Int J Radiat Oncol Biol Phys. 2018; 102: 434-442
- Quality of life analysis of a radiation dose-escalation study of patients with non-small-cell lung cancer: a secondary analysis of the radiation therapy oncology group 0617 randomized clinical trial.JAMA Oncol. 2016; 2: 359-367
- Proton beam radiotherapy and concurrent chemotherapy for unresectable stage III non-small cell lung cancer: final results of a phase 2 study.JAMA Oncol. 2017; 3: e172032
- Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.Lancet. 2009; 374: 379-386
- Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease.Lung Cancer. 2016; 96: 56-62
- Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy.Ann Surg Oncol. 2014; 21: 2083-2090
- Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer.Lancet Oncol. 2008; 9: 636-648
- Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.Lancet. 2015; 386: 1049-1056
- A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903).Cancer. 2012; 118: 6126-6135
- Is neoadjuvant chemoradiotherapy a feasible strategy for stage IIIA-N2 non-small cell lung cancer? Mature results of the randomized IFCT-0101 phase II trial.Lung Cancer. 2010; 69: 86-93
- Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data.Lancet. 2015; 375: 1267-1277
- Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on neew data.Oncologist. 2011; 16: 672-681
- Postoperative radiotherapy for non-small cell lung cancer.Cochrane Database Syst Rev. 2015; (CD002142)
- Postoperative radiotherapy for stage II or III non-small-cell lung caner using the surveillance, epidemiology, and end results database.J Clin Oncol. 2006; 24: 2998-3006
- The risk of death from heart diseae in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: Analysis of the Surveillance , Epidemiology, and End Results database.Cancer. 2007; 110: 911-917
- Impact of postoperative radiation therapy on survival in patietns with complete resection and stage I, II or IIIA non-small-cell lung cancer treated witih adjuvant chemotherapy: The Adjuvant Navelbine International Trialist Association (ANITA) randomized trial.Int J Radiat Oncol Biol Phys. 2008; 72: 695-701
- Postoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data Base.J Clin Oncol. 2015; 33: 870-876
- The effect of postoperative radiotherapy on the survival of patients with resectable stage III-N2 non-small-cell lung cancer: a systematic review and meta-analysis.Neoplasma. 2019; 2019 ([pii:18123N965])
- Radiation therapy to convert the tumor into an in situ vaccine.Int J Radiat Oncol Biol Phys. 2012; 84: 879-880
- Role of local radiation therapy in cancer immunotherapy.JAMA Oncol. 2015; 1: 1325-1332
- Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.J Exp Med. 2006; 203: 1259-1271
- Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.Lancet Oncol. 2015; 16: e498-e509
- Stereotactic radiation therapy augments antigen-specific pd-1-mediated antitumor immune responses via cross-presentation of tumor antigen.Cancer Immunol Res. 2015; 3: 345-355
- Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation.J Immunol. 2012; 189: 558-566
- Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells.J Immunol. 2004; 173: 2462-2469
- Synergy of radiotherapy and PD-1 blockade in Kras-mutant lung cancer.JCI Insight. 2016; 16: e87415
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.Nature. 2015; 520: 373-377
- Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.Lancet Oncol. 2017; 18: 895-903
Tokito T, MS, Kurata T, et al. Overall Survival with Durvalumab vs. Placebo after Chemoradiotherapy in Stage III NSCLC: PACIFIC. 58th annual meeting of Japanese Lung Cancer Society 2017: Yokohama, October 14–15, 2017. p. S1–4.
- Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease.Transl Lung Cancer Res. 2019; 8: 97-106
- Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-smallcell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.Lancet Oncol. 2016; 17: 1672-1682
- Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial.JAMA Oncol. 2018; 4: e173501
- Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial.BMC Cancer. 2012; 12: 305
- A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).Radiother Oncol. 2018; 129: 257-263
- Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer.J Thorac Oncol. 2012; 7: 1807-1814
- The role of radiotherapy in epidermal growth factor receptor mutation-positive patients with oligoprogression: a matched-cohort analysis.Clin Oncol (R Coll Radiol). 2017; 29: 568-575
Article info
Publication history
Published online: October 30, 2019
Identification
Copyright
© 2019 Elsevier Inc. All rights reserved.
